|
11 Companies |
|
9 Products |
|
9 Products |
|
5 Mechanisms of Action |
|
0 Trials |
|
46 News |
|
- ||||||| Trial completion: Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (clinicaltrials.gov) - Jul 18, 2017
P3, N=82, Completed, Sponsor: CSL Behring
Active, not recruiting --> Completed
- Campath (alemtuzumab) / Sanofi
Enrollment change, Trial primary completion date: Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) (clinicaltrials.gov) - May 18, 2017
P4, N=0, Withdrawn, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed N=16 --> 0 | Trial primary completion date: Dec 2015 --> Aug 2016
- ||||||| Trial completion: Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. (clinicaltrials.gov) - Nov 15, 2016
P3, N=106, Completed, Sponsor: Novartis Pharmaceuticals
N=16 --> 0 | Trial primary completion date: Dec 2015 --> Aug 2016 Active, not recruiting --> Completed
- Trial completion, MRI: MRI in Diagnosing and Monitoring CIDP (clinicaltrials.gov) - Oct 26, 2016
P=N/A, N=39, Completed, Sponsor: University of Aarhus
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- ||||||| Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Trial completion, Enrollment change, Trial primary completion date: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) (clinicaltrials.gov) - Oct 6, 2016
P3, N=172, Completed, Sponsor: CSL Behring
Enrolling by invitation --> Completed Active, not recruiting --> Completed | N=350 --> 172 | Trial primary completion date: Dec 2016 --> Sep 2016
- ||||| Enrollment closed: Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (clinicaltrials.gov) - Aug 11, 2016
P3, N=82, Active, not recruiting, Sponsor: CSL Behring
Active, not recruiting --> Completed | N=350 --> 172 | Trial primary completion date: Dec 2016 --> Sep 2016 Enrolling by invitation --> Active, not recruiting
- H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Enrollment change, Trial withdrawal: Pilot Study of Acthar (clinicaltrials.gov) - Jul 19, 2016
P2, N=0, Withdrawn, Sponsor: Mamatha Pasnoor, MD
Enrolling by invitation --> Active, not recruiting N=20 --> 0 | Not yet recruiting --> Withdrawn
- ||||| Enrollment closed, Enrollment change, Trial primary completion date: Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. (clinicaltrials.gov) - May 23, 2016
P3, N=106, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=20 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | N=176 --> 106 | Trial primary completion date: Mar 2017 --> Jul 2016
- Trial completion, HEOR: Effect of Resistance and Aerobic Exercise in CIDP or MMN (clinicaltrials.gov) - May 12, 2016
P=N/A, N=23, Completed, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting | N=176 --> 106 | Trial primary completion date: Mar 2017 --> Jul 2016 Enrolling by invitation --> Completed
- || Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial completion: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. (clinicaltrials.gov) - Jan 20, 2016
P3, N=49, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Enrolling by invitation --> Completed Enrolling by invitation --> Completed
- Enrollment change, HEOR: Effect of Resistance and Aerobic Exercise in CIDP or MMN (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=23, Enrolling by invitation, Sponsor: University of Aarhus
Enrolling by invitation --> Completed N=36 --> 23
- ||||| Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Enrollment closed, Trial primary completion date: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) (clinicaltrials.gov) - Dec 21, 2015
P3, N=350, Active, not recruiting, Sponsor: CSL Behring
N=36 --> 23 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Dec 2016
- Trial primary completion date, MRI: MRI in Diagnosing and Monitoring CIDP (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=40, Enrolling by invitation, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Dec 2016 Trial primary completion date: Sep 2015 --> Apr 2016
- Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial primary completion date: Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP (clinicaltrials.gov) - Nov 12, 2015
P2/3, N=2, Terminated, Sponsor: Octapharma
Trial primary completion date: Sep 2015 --> Apr 2016 Trial primary completion date: Apr 2014 --> Oct 2012
- ||||| Enrollment change: Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (clinicaltrials.gov) - Nov 6, 2015
P3, N=80, Enrolling by invitation, Sponsor: CSL Behring
Trial primary completion date: Apr 2014 --> Oct 2012 N=40 --> 80
- Gammanorm (human immune globulin subcutaneous) / Octapharma
Trial completion, Enrollment change: Immunoglobulin Dosage and Administration Form in CIDP and MMN (clinicaltrials.gov) - Sep 22, 2015
P=N/A, N=36, Completed, Sponsor: Rigshospitalet, Denmark
N=40 --> 80 Active, not recruiting --> Completed | N=45 --> 36
- Trial primary completion date, HEOR: Effect of Resistance and Aerobic Exercise in CIDP or MMN (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=36, Enrolling by invitation, Sponsor: University of Aarhus
Active, not recruiting --> Completed | N=45 --> 36 Trial primary completion date: Jun 2015 --> Dec 2015
- Trial primary completion date, MRI: MRI in Diagnosing and Monitoring CIDP (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=40, Enrolling by invitation, Sponsor: University of Aarhus
Trial primary completion date: Jun 2015 --> Dec 2015 Trial primary completion date: Jun 2015 --> Sep 2015
- | Enrollment change, Trial primary completion date: Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (clinicaltrials.gov) - Jun 15, 2015
P3, N=40, Enrolling by invitation, Sponsor: CSL Behring
Trial primary completion date: Jun 2015 --> Sep 2015 N=70 --> 40 | Trial primary completion date: Feb 2017 --> Aug 2017
- Gammanorm (human immune globulin subcutaneous) / Octapharma
Enrollment closed, Trial primary completion date: Immunoglobulin Dosage and Administration Form in CIDP and MMN (clinicaltrials.gov) - May 5, 2015
P=N/A, N=45, Active, not recruiting, Sponsor: Rigshospitalet, Denmark
N=70 --> 40 | Trial primary completion date: Feb 2017 --> Aug 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Aug 2015
- |||| Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Trial primary completion date: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) (clinicaltrials.gov) - May 4, 2015
P3, N=350, Recruiting, Sponsor: CSL Behring
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Aug 2015 Trial primary completion date: Nov 2015 --> Sep 2016
- |||| Trial primary completion date: Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. (clinicaltrials.gov) - Apr 25, 2015
P3, N=156, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2015 --> Sep 2016 Trial primary completion date: Feb 2016 --> Feb 2017
- Enrollment open, Trial initiation date, Trial primary completion date, MRI: MRI in Diagnosing and Monitoring CIDP (clinicaltrials.gov) - Dec 7, 2014
P=N/A, N=37, Enrolling by invitation, Sponsor: University of Aarhus
Trial primary completion date: Feb 2016 --> Feb 2017 Not yet recruiting --> Enrolling by invitation | Initiation date: Jan 2014 --> May 2014 | Trial primary completion date: Dec 2014 --> Jun 2015
- Enrollment open, HEOR: Effect of Resistance and Aerobic Exercise in CIDP or MMN (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=36, Enrolling by invitation, Sponsor: University of Aarhus
Not yet recruiting --> Enrolling by invitation | Initiation date: Jan 2014 --> May 2014 | Trial primary completion date: Dec 2014 --> Jun 2015 Not yet recruiting --> Enrolling by invitation
- Gammanorm (human immune globulin subcutaneous) / Octapharma
Trial primary completion date: Immunoglobulin Dosage and Administration Form in CIDP and MMN (clinicaltrials.gov) - Nov 4, 2014
P=N/A, N=45, Recruiting, Sponsor: Rigshospitalet, Denmark
Not yet recruiting --> Enrolling by invitation Trial primary completion date: Oct 2014 --> Mar 2015
- | Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Enrollment status, Trial primary completion date: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. (clinicaltrials.gov) - Oct 17, 2014
P3, N=48, Enrolling by invitation, Sponsor: Nihon Pharmaceutical Co., Ltd
Trial primary completion date: Oct 2014 --> Mar 2015 Recruiting --> Enrolling by invitation | Trial primary completion date: Mar 2015 --> Sep 2015
- |||| Trial primary completion date: Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. (clinicaltrials.gov) - Sep 30, 2014
P3, N=156, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Enrolling by invitation | Trial primary completion date: Mar 2015 --> Sep 2015 Trial primary completion date: Nov 2016 --> Feb 2016
- prednisone / Generic mfg.
Trial completion: PRNC: Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg (clinicaltrials.gov) - Sep 28, 2014
P3, N=40, Completed, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Trial primary completion date: Nov 2016 --> Feb 2016 Recruiting --> Completed
- |||||| Enrollment open: Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (clinicaltrials.gov) - Aug 11, 2014
P3, N=70, Enrolling by invitation, Sponsor: CSL Behring
Recruiting --> Completed Not yet recruiting --> Enrolling by invitation
- HEOR: Effect of Resistance and Aerobic Exercise in CIDP or MMN (clinicaltrials.gov) - Apr 21, 2014
P=N/A, N=36, Not yet recruiting, Sponsor: University of Aarhus
- Gammanorm (human immune globulin subcutaneous) / Octapharma
Clinical: Immunoglobulin Dosage and Administration Form in CIDP and MMN (clinicaltrials.gov) - Apr 9, 2014
P=N/A, N=45, Recruiting, Sponsor: Rigshospitalet, Denmark
- | Avonex (recombinant IFN-?-1a) / Biogen
Trial completion: Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (clinicaltrials.gov) - Feb 22, 2014
P2, N=67, Completed, Sponsor: Biogen Idec
Not yet recruiting --> Enrolling by invitation No longer recruiting --> Completed
- |||||||||| New P3 trial: Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (clinicaltrials.gov) - Jan 2, 2014
P3, N=70, Not yet recruiting, Sponsor: CSL Behring
- MRI: MRI in Diagnosing and Monitoring CIDP (clinicaltrials.gov) - Dec 19, 2013
P=N/A, N=37, Not yet recruiting, Sponsor: University of Aarhus
- ||||| Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Enrollment change: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) (clinicaltrials.gov) - Oct 9, 2013
P3, N=350, Recruiting, Sponsor: CSL Behring
No longer recruiting --> Completed N=250 --> 350
- | Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Enrollment open: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. (clinicaltrials.gov) - Jul 9, 2013
P3, N=48, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
N=250 --> 350 Not yet recruiting --> Recruiting
- | Enrollment open: Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. (clinicaltrials.gov) - Apr 27, 2013
P3, N=156, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Ongoing --> Recruiting
- ||| Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
New P3 trial: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. (clinicaltrials.gov) - Apr 2, 2013
P3, N=48, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
- Campath (alemtuzumab) / Sanofi
New P4 trial: Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) (clinicaltrials.gov) - Dec 27, 2012
P4, N=16, Recruiting, Sponsor: Johns Hopkins University
- Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial termination: Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP (clinicaltrials.gov) - Sep 9, 2012
P2/3, N=2, Terminated, Sponsor: Octapharma
Ongoing --> Recruiting Suspended --> Terminated; Study Terminated.priority changes in product development.
- Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Enrollment change: Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP (clinicaltrials.gov) - Sep 9, 2012
P2/3, N=2, Terminated, Sponsor: Octapharma
Suspended --> Terminated; Study Terminated.priority changes in product development. N=172 --> 2
- || New P3 trial: Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. (clinicaltrials.gov) - Jun 19, 2012
P3, N=156, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||||| Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Enrollment open: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) (clinicaltrials.gov) - Mar 11, 2012
P3, N=350, Recruiting, Sponsor: CSL Behring
N=172 --> 2 Not yet recruiting --> Recruiting
- |||||||||| Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
New P3 trial: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) (clinicaltrials.gov) - Mar 4, 2012
P3, N=350, Recruiting, Sponsor: CSL Behring
- || Privigen (human immune globulin intravenous 10%) / CSL Behring
Trial completion: Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (clinicaltrials.gov) - Jan 18, 2012
P3, N=31, Completed, Sponsor: CSL Behring
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Subcuvia (human normal immunoglobulin 16%) / Takeda
Trial completion: Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (clinicaltrials.gov) - Nov 8, 2011
P2, N=30, Completed, Sponsor: University of Aarhus
Active, not recruiting --> Completed Active, not recruiting --> Completed